Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 16 de 16
Filtrer
1.
Transplant Proc ; 56(4): 948-952, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38729829

RÉSUMÉ

BACKGROUND: Pre-transplantation dialysis duration and modality may affect patients' long-term (mortality and graft failure) and short-term (delayed graft function) outcomes after kidney transplantation. We aimed to assess the impact of the method and duration of dialysis therapy on the graft function in the first 6 months post-transplant. METHODS: The analysis included 122 kidney transplant patients (109 from a deceased donor and 13 from a living donor). Before transplantation, 91 were on hemodialysis (HD), 19 were on peritoneal dialysis (PD), and 9 received preemptive transplants. The incidence of delayed graft function (DGF) and creatinine levels at discharge and 6 months after transplantation were assessed. RESULTS: PD and HD patients did not differ in age, number of mismatches, and cold ischemia time (CIT), but they had a significantly shorter dialysis vintage (18.3 ± 25.7 vs 39.6 ± 34.3 months, P = .01) and a lower incidence of DGF (5% vs 37%, P = .006). The duration of hospitalization and creatinine concentration at discharge and after 6 months were similar. Preemptively transplanted patients had a significantly shorter CIT (ND vs DO - 576 ± 362 vs 1113 ± 574, P = .01; ND vs HD - 576 ± 362 vs 1025 ± 585 minutes, P = .01). DGF did not occur in any of the patients transplanted preemptively. They had slightly shorter hospitalization times and, compared to HD, better graft function at discharge. After 6 months, creatinine levels were comparable to HD and PD. Patients dialyzed for less than 12 months, regardless of the method, had a lower incidence of DGF. CONCLUSIONS: Peritoneal dialysis and a short duration of pre-transplant dialysis may improve the early results of kidney transplantation.


Sujet(s)
Reprise retardée de fonction du greffon , Transplantation rénale , Dialyse rénale , Humains , Femelle , Mâle , Adulte d'âge moyen , Adulte , Résultat thérapeutique , Reprise retardée de fonction du greffon/étiologie , Reprise retardée de fonction du greffon/épidémiologie , Facteurs temps , Créatinine/sang , Dialyse péritonéale , Survie du greffon
2.
Transplant Proc ; 56(4): 806-812, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38729832

RÉSUMÉ

BACKGROUND: Long-lasting diabetes mellitus type 1 and end-stage renal disease induce severe metabolic and immunologic deterioration. Pretransplant C-reactive protein (CRP) and albumin (ALB) levels impact kidney transplantation. We evaluated the effects of preoperative CRP, ALB, neutrophils (NEU), and platelet (PLT) counts on 1- and 5-year recipient survival after simultaneous pancreas and kidney transplantation (SPK). METHODS: Among 103 SPK recipients, the parameters were as follows: CRP (mean: 4.5 ± 4.97 mg/L); NEU (mean: 5.12 ± 2.13 × 103/mm3); PLT (mean: 244 ± 84 × 103/mm3); ALB (mean 4.5 ± 0.75 g/dL) were obtained before transplantation. Cox regression, uni-, multivariate analysis for 1- and 5-year survivals were performed with 95% CIs, and the area under the receiver operating characteristic (ROC) curve (AUC) was assessed. RESULTS: In Cox regression, ALB <3.65 g/dL significantly affected 1- and 5-year survivors with hazard ratios of 8 (95% CI, 1.5-38.28; P < .05) and 3.13 (95% CI, 1.45-6.73; P < .05), respectively. In univariate analysis, we found significantly decreased 1-year survival when PLT <180×103/mm3, ALB <3.65 g/dL, NEU >5.8×103/mm3 and CRP >2.25 mg/L with odds ratios (OR) of 6.75 (95% CI, 2.12-21.15); 4.05 (95% CI, 1.3-12.09); 2.97 (95% CI, 1.02-8.64) and 5.51 (95% CI, 1.67-18.19), respectively. Independent factors for 5-year survival were CRP, ALB, and PLT with OR of 4.72 (95% CI, 1.67-13.29), 3.31 (95% CI, 1.18-9.25), and 4.2 (95% CI, 1.39-12.68), respectively. In multivariate analysis, we built 2 models for 1-year survival. Model 1 (ALB+PLT) with ORs of 3.12 (95% CI, 0.97-10.07) and 5.55 (95% CI, 1.67-18.4); and model 2 (CRP+PLT) with ORs of 5.51 (95% CI, 1.5-17.3) and 4.3 (95% CI, 1.2-15.06), respectively. The AUC for models 1 and 2 were 0.74 and 0.759, respectively. CONCLUSIONS: NEU, PLT, ALB, and CRP levels assessed before transplantation are independent factors for 1- and 5-year SPK recipient survival.


Sujet(s)
Protéine C-réactive , Transplantation rénale , Granulocytes neutrophiles , Transplantation pancréatique , Humains , Protéine C-réactive/analyse , Transplantation pancréatique/mortalité , Mâle , Femelle , Adulte , Adulte d'âge moyen , Plaquettes/métabolisme , Défaillance rénale chronique/chirurgie , Numération des plaquettes , Sérumalbumine/analyse , Diabète de type 1/chirurgie , Diabète de type 1/mortalité , Diabète de type 1/sang , Études rétrospectives , Survie du greffon , Modèles des risques proportionnels
3.
Front Cardiovasc Med ; 10: 1153130, 2023.
Article de Anglais | MEDLINE | ID: mdl-37745097

RÉSUMÉ

Extracellular Neutrophils Traps (NETs) and their formation, known as NETosis, have become pivotal in the pathogenesis of aortic aneurysm development. This study investigates the NETosis markers with the assessment of selected parameters of inflammation and coagulation system in patients with thoracoabdominal aortic aneurysms in the pre-and postop period undergoing t-Branch stent-graft implantation. The study included 20 patients with thoracoabdominal aortic aneurysms. Three markers double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), and citrullinated H3 histones (Cit-H3) were tested at three-time points from patients' blood. The parameters of NETosis, inflammation, and coagulation system were examined in the preoperative period (within 24 h before surgery) and in the postoperative period (on the 3rd and 5th postoperative day). Free-circulating DNA (cfDNA) was isolated from the blood using the MagMAXTM Cell-Free DNA Extraction Kit. Double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA) were then quantified using the Qubit dsDNA HS Assay Kit and the Qubit ssDNA Assay Kit. Cit-H3 concentration was determined by enzyme immunoassay ELISA (Cayman). The results revealed the significance of NETs secretion in response to the complex processes after stent-graft implantation. All NET markers increased shortly after surgery, with histones being the first to return to preoperative levels. The lack of normalization of dsDNA and ssDNA levels to preoperative levels by the last postoperative blood collection demonstrates NETs reorganization. The increase in the number of neutrophils was not related to the expansion of postoperative NETosis. The study reveals a new marker of NETosis, ssDNA, that has not been studied so far. The implantation of a stent graft in a patient with TAAA triggers an inflammatory response manifested by an increase in inflammatory parameters. One of the hallmarks of inflammation is the activation of neutrophil extracellular traps.

4.
Transplant Proc ; 54(4): 890-896, 2022 May.
Article de Anglais | MEDLINE | ID: mdl-35752505

RÉSUMÉ

BACKGROUND: Kidney transplant is the preferred treatment for most patients with end-stage renal disease. Because dialyzed patients often have significant comorbidities or multimorbidities, they should be carefully evaluated before being waitlisted for transplant. The COVID-19 pandemic presents a major challenge for surgery, including transplant surgery. Owing to a fear of COVID-19 symptoms occurring in lungs, thin-section computed tomography (TSCT) became a standard evaluation technique in potential kidney transplant recipients before surgery. METHODS: The aim of the study was to evaluate the rationale and usefulness of TSCT in deceased donor kidney transplant during the COVID-19 pandemic. All adult patients who underwent deceased donor kidney transplant between May 1, 2020, and December 15, 2021, were included in the study. Potential kidney transplant recipients who were admitted to the Department of General, Vascular, and Transplant Surgery at the Medical University of Warsaw in Warsaw, Poland, were tested for COVID-19 (CovGenX rapid test); blood chemistries were performed; dialysis was performed (if needed); and, on a negative reverse transcriptase polymerase chain reaction test, HRCT was performed. RESULTS: From May 2020 until the end of December 2021, 54 patients were transplanted; however, 7 patients were disqualified after TSCT and consulted with a pulmonary specialist. Disqualification from kidney transplant accounted for 13% of the potential kidney allograft recipients. CONCLUSIONS: Despite the possibility of overdiagnosis by TSCT, TSCT should be considered a standard evaluation technique in potential kidney transplant recipients. Potential kidney transplant recipients must be periodically reassessed given the prolonged wait time for a donor kidney and the significant number of comorbid conditions in this patient population. However, more data with longer follow-ups are needed to prove or disprove the rationale to use TSCT in transplant surgery.


Sujet(s)
COVID-19 , Transplantation rénale , Adulte , COVID-19/épidémiologie , Dépistage de la COVID-19 , Humains , Transplantation rénale/effets indésirables , Pandémies , Dialyse rénale , Thorax , Tomographie , Receveurs de transplantation
5.
Transplant Proc ; 54(4): 976-980, 2022 May.
Article de Anglais | MEDLINE | ID: mdl-35637013

RÉSUMÉ

Transplant renal artery stenosis (TRAS) constitutes 75% of all vascular complications in kidney transplant recipients, being a significant source of graft dysfunction and loss. TRAS is a heterogeneous disease with different risk factors and causes. The incidence differs greatly, and it is likely it will increase because of the aging population of potential recipients and donors of renal grafts and the expanding use of extended-criteria donors. Prompt diagnosis and treatment of TRAS can prevent irreversible allograft dysfunction and loss. Current evidence of risk factors, diagnostic challenges, and therapeutic options are presented in this short review.


Sujet(s)
Transplantation rénale , Occlusion artérielle rénale , Sujet âgé , Humains , Transplantation rénale/effets indésirables , Occlusion artérielle rénale/diagnostic , Occlusion artérielle rénale/étiologie , Facteurs de risque , Donneurs de tissus , Transplantation homologue/effets indésirables
6.
Med Sci Monit ; 27: e935134, 2021 Dec 28.
Article de Anglais | MEDLINE | ID: mdl-34961758

RÉSUMÉ

The pathogenesis of the aortic aneurysm (AA) includes several mechanisms, such as chronic sterile inflammation and homeostasis imbalance, with arteriosclerosis, hemodynamic forces, and genetic factors. In addition to the roles of these processes in the development of AA, neutrophilic activity may play a pivotal role (mostly in inflammation and thrombus formation). Neutrophils, which play a crucial role in innate immunity, can release neutrophil extracellular traps (NETs), one of the mechanisms against fighting pathogens, beside phagocytosis and degranulation. NETs are structures composed of nuclear elements (eg, chromatin and modified histones) and granular and cytoplasmic components, which can lead to inflammation and coagulation changes. In addition, the exacerbation of NETosis (the process of NET formation) can be noticed in vascular diseases, including in the development of AA and myocardial infarction and in diabetes, hypertension, and COPD, which are the risk factors of the presence of AA. The discharge of NETs, which are extracellular materials formed by citrullinated histones (Cit-H), cell-free DNA fibers (cf-DNA), and granular and cytoplasmic molecules, is a newly identified method of neutrophil activation that can be activated by endogenous inflammatory stimuli, which contribute to AA development. Cit-H and cf-DNA can be used as biomarkers of AA growth. By understanding the neutrophilic influence of NET release, a new pathway of screening AA growth (by measurement of biomarkers of NETosis) and pharmacological assessment (by repression of NET formation) can be developed. This review summarizes the current knowledge about the influence of NETs on AA growth in human and animal studies.


Sujet(s)
Anévrysme de l'aorte/immunologie , Athérosclérose/immunologie , Pièges extracellulaires/immunologie , Inflammation/immunologie , Granulocytes neutrophiles/immunologie , Thrombose/immunologie , Animaux , Athérosclérose/physiopathologie , Endothélium vasculaire/physiopathologie , Humains , Inflammation/physiopathologie , Thrombose/physiopathologie
7.
Contemp Oncol (Pozn) ; 25(1): 28-32, 2021.
Article de Anglais | MEDLINE | ID: mdl-33911979

RÉSUMÉ

INTRODUCTION: Hypopharyngeal cancer accounts for 3-5% of all squamous-cell carcinoma (SCC) of the head and neck and has one of the worst prognoses. The aim of the study was to evaluate oncologic and functional treatment outcomes in patients with T3-T4a squamous cell hypopharyngeal and laryngeal cancer. MATERIAL AND METHODS: Retrospective analysis of the material from one treatment site included 90 patients (81 male, 9 female) who had undergone surgery between 1986 and 2010. Their mean age was 55.06 years (range 36-75). RESULTS: TNM (T - tumour, N - node, M - metastasis) staging assessment was feasible in 70 treatment-naïve patients (77.78%): 57 (63.33%) were classified to stage T4a, and 13 were classified to T3 (14.44%). Cervical lymphadenopathy was observed in 53 (63.3%) patients; in 44 patients (48.89%) postoperative histopathology confirmed metastatic disease. G2 or G3 SCC was detected in 80% of patients. All patients underwent laryngopharyngoesophagectomy (LPE). Digestive tract reconstruction was performed using one of two methods: jejunal autograft (JA) in 79 patients (87.78 %) - Group A or ileocolic autograft (IA) in 11 patients (12.22%) - Group B. Comparative statistical analysis of both groups showed statistically significant differences only for substitute speech production. The mean survival time of patients from both groups was 2.21 years after reconstruction surgery. CONCLUSIONS: JA or IA for digestive tract reconstruction in patients after LPE are burdened with high risk of complications but offer patients the chance of a normal oral diet shortly after surgery. Ileocolic autograft enables rapid production of substitute speech.

10.
Ann Transplant ; 23: 360-363, 2018 May 25.
Article de Anglais | MEDLINE | ID: mdl-29798972

RÉSUMÉ

BACKGROUND Pre-procurement pancreas suitability score (P-PASS) and pancreas donor risk (PDRI) index are scoring systems believed to predict suitability of pancreatic grafts. Most European countries and the United States apply PDRI, while Poltransplant keeps using P-PASS: more than 16 points raises a red flag for graft use. Recent data discourage use of PDRI to predict pancreas graft survival. The aim of the present study was to assess PDRI and P-PASS as predictors of transplanted pancreas survival in a Polish population. MATERIAL AND METHODS From February 1998 to September 2015, 407 pancreas transplantations were performed in Poland: 370 (90.9%) simultaneous pancreas-kidney transplantation and 37 (9.1%) pancreas transplantation alone or pancreas after kidney. The endpoint was death-uncensored 12-month graft survival with satisfactory glycemic control without insulin. RESULTS Average P-PASS was 15.9±2.66 and PDRI was 0.96±0.37. Recipients who survived 12 months with good graft function had an average P-PASS score of 15.7 and PDRI of 0.95. Recipients with death-uncensored graft loss had a mean P-PASS of 16.4 and PDRI of 0.99. Univariate analysis revealed donor age, body mass index (BMI), and P-PASS to be significant risk factors for 1-year pancreas graft survival. CONCLUSIONS P-PASS, but not PDRI, is a reliable tool to predict pancreas graft survival in the Polish population.


Sujet(s)
Sélection de donneurs/méthodes , Survie du greffon , Transplantation pancréatique/effets indésirables , Donneurs de tissus , Acquisition d'organes et de tissus , Adulte , Femelle , Enquêtes de santé , Humains , Mâle , Transplantation pancréatique/mortalité , Pologne , Facteurs de risque , Receveurs de transplantation , Résultat thérapeutique , Jeune adulte
11.
Pol Arch Intern Med ; 127(3): 178-183, 2017 02 15.
Article de Anglais | MEDLINE | ID: mdl-28220766

RÉSUMÉ

INTRODUCTION    Antibodies against donor human leukocyte antigens (HLAs) play a significant role in the pathogenesis of antibody­mediated rejection, although their relevance during the late posttransplant period is unknown. A non­HLA polymorphic antigenic system, like major histocompatibility class I chain­related antigen A (MICA), might be another target for antibody responses involved in rejection. OBJECTIVES    We conducted a 7­year prospective study to determine the effect of positivity for anti­HLA and anti­MICA antibodies on kidney graft survival. PATIENTS AND METHODS    A random blood sample was collected from 457 kidney recipients during a regular outpatient visit. Patients who were less than 6 months after transplantation were excluded. Evaluation of anti­HLA (classes I and II) and anti-MICA antibodies was performed with the use of Luminex assays. An outpatient registry was used to monitor kidney function during a 7­year follow­up. RESULTS    A total of 147 patients (32%) had anti­HLA and 88 patients (19%) had anti­MICA antibodies. Graft failure occurred in 67 anti­HLA­positive individuals (46%) as compared to 81 anti­HLA­negative ones (26%) (P <0.05), and in 30 anti­MICA­positive individuals (34%) as compared to 118 anti­MICA­negative ones (32%) (P = 0.52). Anti­HLA antibodies were associated with increased incidence of graft failure: it was reported in 200 patients with an estimated glomerular filtration rate of more than 30 ml/min/1.73 m2 body surface area more than 5 years after transplantation (P <0.005). CONCLUSIONS    Anti­HLA, but not anti­MICA, antibodies in randomly obtained blood samples were the significant predictor of late kidney graft failure and could be a low­cost method enabling identification of patients requiring an individualized posttransplant approach. The results of our study provide an additional rationale for investigating immune biomarkers in certain diseases.


Sujet(s)
Rejet du greffon/sang , Antigènes d'histocompatibilité/immunologie , Alloanticorps/sang , Maladies du rein/chirurgie , Transplantation rénale/mortalité , Adulte , Marqueurs biologiques/sang , Femelle , Études de suivi , Rejet du greffon/diagnostic , Humains , Mâle , Adulte d'âge moyen , Pronostic , Études prospectives
12.
Wideochir Inne Tech Maloinwazyjne ; 11(4): 283-287, 2016.
Article de Anglais | MEDLINE | ID: mdl-28194249

RÉSUMÉ

INTRODUCTION: The advantages of a minimally invasive nephrectomy are a faster recovery and better quality of life for the donors. Until recently, the majority of donor nephrectomies in Poland were done by open surgery. AIM: To present a single centre experience in hand-assisted laparoscopic donor nephrectomy (HALDN). MATERIAL AND METHODS: The first videoscopic left donor nephrectomy in Poland was performed in our department in 2003 using a hand-assisted retroperitoneal approach. From 2011, we changed the method to a transperitoneal approach and started to harvest also right kidneys. Since then, it has become the method of choice for donor nephrectomy and has been performed in 59 cases. Preoperatively, kidneys were assessed by scintigraphy and by angio-computed tomography. We harvested 32 left and 27 right kidneys. There were double renal arteries in 2 cases and triple renal arteries in 1 case. The warm ischaemia time (WIT) was 80-420 s (average 176.13 s); operative time was 85-210 min (average 140 min). RESULTS: All procedures were uncomplicated, and all donors were discharged after 2-8 days with normal creatinine levels. The average follow-up period lasted 23 months (1-51 months). Out of all of the cases, 1 case had two minor complications, while all others were uneventful. None of the donors were lost to follow-up. All of the kidneys were transplanted. There were 2 cases of delayed graft function (DGF) and 2 cases of ureter necrosis. One of those kidneys was lost in the third postoperative week. CONCLUSIONS: Our limited experience shows that HALDN is a safe method and should be used routinely instead of open surgery.

13.
Ann Transplant ; 11(1): 40-2, 2006.
Article de Anglais | MEDLINE | ID: mdl-17025029

RÉSUMÉ

Simultaneous pancreas and kidney transplantation (spktx) is currently the most effective method of treatment of type 1 diabetes complicated by renal insufficiency. The first successful spktx in Poland was performed in the Department of General, Vascular and Transplant Surgery of the Warsaw Medical University on the 4th of February 1988. Since then 70 spktx were performed in our Department. We present a 44-year-old patient who after 16 years of good function of both transplanted organs presented with elevated creatinine levels (>4 mg/dl) as a result of chronic rejection of the kidney allograft. On the 22nd of January 2005 the patient underwent secondary kidney transplantation. The immunosuppresive protocol consisted of MMF, CsA and steroids. Humanized anti-lL-2 monoclonal antibodies (daclizumab) were used as pre-procedure induction. Using a mid-line incision the new kidney graft was anastomosed to the recipient left external iliac vessels. The ureter was anastomosed with the bladder without anti reflux procedures and the allograft was placed in the retroperitoneum below the previously transplanted kidney. Graftectomy of the first kidney allograft was not performed. After surgery, normal creatinine parameters were restored to a level of 1, 1 mg/dl and an increase in urine output was noted from 1 to 4 liters per day. Oral intake of foods was resumed on the 4th postoperative day and no early complications were observed. 12 months observation period confirmed stabile function of both transplanted organs. Secondary kidney transplantation in patients after spktx is technically possible and may be considered an option in patients with diminishing function of the first kidney allograft.


Sujet(s)
Transplantation rénale/physiologie , Transplantation pancréatique/physiologie , Réintervention , Adulte , Femelle , Rejet du greffon/chirurgie , Humains , Transplantation rénale/anatomopathologie , Transplantation pancréatique/anatomopathologie , Pologne
14.
Ann Transplant ; 11(2): 57-9, 2006.
Article de Anglais | MEDLINE | ID: mdl-17494291

RÉSUMÉ

OBJECTIVES: The feasibility and timing of corticosteroid elimination and its impact on lipid metabolism in simultaneous pancreas and preemptive kidney transplantation were examined. MATERIAL AND METHODS: A retrospective study was conducted on 14 recipients of pancreas and preemptive kidney grafts transplanted form April 2003 to March 2004. All recipients received ATG induction. Tacrolimus (Tac) was administered according to trough concentration 8-15 ng/ml. Mycophenolate mofetil (MMF) was administered at doses of 2 g per day with subsequent dosage adjustment based on tolerability. All recipients received corticosteroids with subsequent dose tapering. Total cholesterol and triglyceride levels before transplantation and after steroid withdrawal were assessed. RESULTS: One year recipient survival rate was 100%. Cumulative one year panaceas and kidney survival rates were: 85% and 100%, respectively. After transplantation of fasting glycemia and HbAIC were normalized. Serum creatinine decreased from 4.35 +/- 1.61 mg/dl before transplantation to 1.1 + 0.25 mg/dl after surgery (p < 0.05). Corticosteroids were eliminated between the 2nd and 16th month (mean 6 months) after transplantation. Cholesterol and triglyceride levels were wiyhin normal range, in addition significantly decreased after transplantation and steroid withdrawal, from 194.5 +/- 35.6 mg/dl to 162.4 +/- 36.8 mg/dl and 142.5 +/- 65 94.8 +/- 42.5 mg/dl, respectively (p < 0.05). CONCLUSIONS: It is possible to eliminate steroids 6 months after transplantation using immunossupression based on MMF and Tac. Withdrawal of steroids could be partially contributed to the normalization of lipid metabolism.


Sujet(s)
Hormones corticosurrénaliennes/effets indésirables , Transplantation rénale , Transplantation pancréatique , Hormones corticosurrénaliennes/administration et posologie , Adulte , Sérum antilymphocyte/usage thérapeutique , Diabète de type 1/complications , Néphropathies diabétiques/anatomopathologie , Études de faisabilité , Femelle , Humains , Immunosuppresseurs/sang , Immunosuppresseurs/usage thérapeutique , Transplantation rénale/immunologie , Transplantation rénale/mortalité , Mâle , Adulte d'âge moyen , Acide mycophénolique/analogues et dérivés , Acide mycophénolique/sang , Acide mycophénolique/usage thérapeutique , Transplantation pancréatique/immunologie , Transplantation pancréatique/mortalité , Études rétrospectives , Taux de survie , Tacrolimus/sang , Tacrolimus/usage thérapeutique , Facteurs temps , Transplantation homologue
15.
Ann Transplant ; 10(3): 31-5, 2005.
Article de Anglais | MEDLINE | ID: mdl-16617664

RÉSUMÉ

OBJECTIVE: A cohort study was conducted to compare treatment of patients with type 1 diabetes mellitus and end-stage diabetic nephropathy. PATIENTS AND METHODS: 47 type 1 diabetic patients required renal replacement therapy in years: 2001-2005 were enrolled. Simultaneous pancreas and preemptive kidney transplant (sppktx) was performed in 18 (group I). Group II consisted of 29 patients who entered dialysis program. Survival rate for patients from both groups was estimated. Transplanted organ function was evaluated for group II. Lipid profile and its correlation with thickness of carotid media was assessed. Impact of sppktx on diabetic retinopathy was investigated. Cost and life quality were compared between groups. RESULTS: Two-year cumulative recipient survival rate for group I and II was 100% and 96%, respectively. One-year cumulative survival rate for transplanted pancreas was 88% and for kidney grafts 94%. In group I cholesterol and triglyceride level before transplantation were: 207 +/- 38 mg/dl and 133 +/- 65 mg/dl and decreased after transplantation to 155 +/- 20 mg/dl and 78 +/- 25 mg/dl, respectively (p < 0.05). No difference of carotid media thickness was observed between groups. Stabilization of retinopathy was observed in 91.6% non-blind recipients. During the first year of the follow-up the costs of transplantation doubled those of dialysis therapy but in the second year the costs of dialysis exceeded the costs required for transplanted patients. CONCLUSION: Despite of major surgery and introduction of immunosuppression in group I, results did not differ significantly between groups during a two-year follow-up. After sppktx, stabilization of the carotid media was slower than the normalization of lipids. At the second year, transplantation is less expensive than dialysis.


Sujet(s)
Diabète de type 1/thérapie , Néphropathies diabétiques/thérapie , Défaillance rénale chronique/thérapie , Transplantation rénale , Transplantation pancréatique , Dialyse rénale , Adulte , Études de cohortes , Diabète de type 1/complications , Diabète de type 1/mortalité , Néphropathies diabétiques/complications , Néphropathies diabétiques/mortalité , Femelle , Humains , Hypoglycémiants/usage thérapeutique , Insuline/usage thérapeutique , Défaillance rénale chronique/étiologie , Défaillance rénale chronique/mortalité , Mâle , Adulte d'âge moyen , Taux de survie , Résultat thérapeutique
16.
Transpl Int ; 15(9-10): 455-8, 2002 Oct.
Article de Anglais | MEDLINE | ID: mdl-12389076

RÉSUMÉ

A matched case-control study was performed to compare the prognosis of six renal transplant recipients with a control group of non-transplant patients, both groups presenting with native kidney tumors. Patients were matched for age, gender, neoplasm histology, and TNM classification. The follow-up ranged from 8 to 131 months (median 32 months) after nephrectomy or nephroureterectomy of the native kidney. Five out of six recipients retained good graft function. No evidence of recurrent local disease or distant metastasis of kidney neoplasms was observed in either group. In the transplant group, two patients developed basal cell carcinoma, and one, lung cancer and a disseminated lymphoma. Among control group patients, prostate and bladder cancer were noted. Prognosis of early-stage kidney malignancy in the transplant and non-transplant group was comparable despite immunosuppression; however, recovery from the primary kidney malignancy did not exclude the risk of developing a new type of neoplasm in either group.


Sujet(s)
Tumeurs du rein/épidémiologie , Transplantation rénale/effets indésirables , Adulte , Sujet âgé , Études cas-témoins , Femelle , Études de suivi , Humains , Tumeurs du rein/anatomopathologie , Transplantation rénale/physiologie , Mâle , Adulte d'âge moyen , Invasion tumorale , Néphrectomie , Complications postopératoires/épidémiologie , Pronostic , Facteurs temps
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...